Trial Profile

Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 01 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adrabetadex (Primary) ; Adrabetadex (Primary)
Indications Liver disorders; Neurological disorders; Niemann-Pick disease type C
Focus Adverse reactions

Most Recent Events

11 Jul 2022 According to ClinicalTrials.gov record, protocol has been amended to decrease treatment arm from 3 to 2
11 Jul 2022 Status changed from completed to discontinued.
27 Oct 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com